Bamlanivimab

Kathryn Dzintars, Pharm.D., BCPS
Bamlanivimab is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • The FDA issued an Emergency Use Authorization (EUA) permitting the use of bamlanivimab for the treatment of mild to moderate coronavirus disease in adult and pediatric (≥ 12 years of age; ≥40 kg) with a positive SARS-CoV-2 test who are at high risk* for progressing to severe disease or hospitalization. This EUA restricts treatment to outpatient administration only. It is not approved for use within hospitals.
    • FDA issued a EUA (2/4/21) for the combination of bamlanivimab and etesevimab.
  • *High risk is defined as:
    • Have a body mass index (BMI) ≥ 35
    • Have chronic kidney disease
    • Have diabetes
    • Have immunosuppressive disease
    • Are currently receiving immunosuppressive treatment
    • Are ≥65 years of age
    • ≥ 55 years of age AND must have one of the following
      • Cardiovascular disease OR
      • Hypertension OR
      • COPD/other chronic respiratory diseases
    • Are 12 – 17 years of age AND have one of the following
      • BMI ≥85th percentile for their age and gender based on CDC growth charts (https://www.cdc.gov/growthcharts/clinical_charts.htm), OR
      • Sickle cell disease, OR
      • Congenital or acquired heart disease, OR
      • Neurodevelopmental disorders, for example, cerebral palsy, OR
      • Medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
      • Asthma, reactive airway or other chronic respiratory diseases that require daily medication for control.

Bamlanivimab is NOT authorized for use in patients:

  • Who are hospitalized due to COVID-19, or
  • Who require oxygen therapy due to COVID-19, or
  • Who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • The FDA issued an Emergency Use Authorization (EUA) permitting the use of bamlanivimab for the treatment of mild to moderate coronavirus disease in adult and pediatric (≥ 12 years of age; ≥40 kg) with a positive SARS-CoV-2 test who are at high risk* for progressing to severe disease or hospitalization. This EUA restricts treatment to outpatient administration only. It is not approved for use within hospitals.
    • FDA issued a EUA (2/4/21) for the combination of bamlanivimab and etesevimab.
  • *High risk is defined as:
    • Have a body mass index (BMI) ≥ 35
    • Have chronic kidney disease
    • Have diabetes
    • Have immunosuppressive disease
    • Are currently receiving immunosuppressive treatment
    • Are ≥65 years of age
    • ≥ 55 years of age AND must have one of the following
      • Cardiovascular disease OR
      • Hypertension OR
      • COPD/other chronic respiratory diseases
    • Are 12 – 17 years of age AND have one of the following
      • BMI ≥85th percentile for their age and gender based on CDC growth charts (https://www.cdc.gov/growthcharts/clinical_charts.htm), OR
      • Sickle cell disease, OR
      • Congenital or acquired heart disease, OR
      • Neurodevelopmental disorders, for example, cerebral palsy, OR
      • Medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
      • Asthma, reactive airway or other chronic respiratory diseases that require daily medication for control.

Bamlanivimab is NOT authorized for use in patients:

  • Who are hospitalized due to COVID-19, or
  • Who require oxygen therapy due to COVID-19, or
  • Who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: February 15, 2021